FDA Breakthrough Therapy Designations 2018
Purdue to pay over $8bn to settle opioid-related criminal claims
Claims relate to Purdue's involvement in fuelling the opioid addiction crisis
Mallinckrodt files for bankruptcy protection in the US
Bankruptcy filing will reduce debts related to legal liabilities
Mallinckrodt reaches tentative $1.6bn opioid settlement
Agreement reached with a plaintiff's executive committee
FDA committee rejects Intellipharmaceutics’ opioid drug Aximris
Verdict closely follows rejection of Nektar’s opioid analgesic
Nektar’s opioid analgesic slammed with FDA panel rejection
Panelists unanimously rejected use of the chronic back pain drug
J&J appeals Oklahoma opioid verdict, claiming ‘errors’ in trial
Cites misuse of public nuisance laws as grounds for appeal
Teva names new CFO and bulks up its opioid liability fund
Opioid liability issue overshadowed the company's Q3 results
UPDATED: Ohio opioid trial averted by last-minute settlement
Drug manufacturers reach settlement hours before trial set to begin
J&J proposes $4bn in cash to settle opioid crisis allegations
Upcoming federal trial puts a number of companies in the spotlight
Purdue Pharma files for bankruptcy after opioid settlement
Company has faced brunt of blame for fuelling epidemic
Prescription drug dependence ‘linked to deprivation’, says PHE
Public Health England publishes review on prescription rates